Devan Marar, MD
Cardiovascular Disease (Cardiology) · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Marar’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A107787 · Current
Licensed to practise in California · since 2009 · expires 2026-11-30 · Virginia Commonwealth University, Medical College of Virginia.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$189,792
Medicare paid this office $189,792 for 929 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 327 | $56,413 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $23,374 | $169 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $11,173 | $430 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 199 | $10,962 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $10,482 | $144 |
See all 30 services
| Return visit (30+ min) | 327 | $56,413 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $23,374 | $169 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $11,173 | $430 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 199 | $10,962 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $10,482 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $10,440 | $103 |
| New patient visit (45+ min) | 67 | $9,411 | $140 |
| Short return visit (20+ min) | 85 | $8,171 | $80 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 30 | $6,927 | $231 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,892 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 353 | $4,757 | $12 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 25 | $3,811 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,108 | $111 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 179 | $2,912 | $14 |
| 3d radiographic procedure | 87 | $2,276 | $26 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 228 | $2,248 | $7 |
| Programming of dual lead pacemaker system | 17 | $2,043 | $76 |
| Ultrasound of heart blood flow, valves and chambers | 27 | $1,372 | $51 |
| External shock to heart to regulate heart beat | 13 | $1,261 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,123 | $94 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 40 | $881 | $22 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 22 | $818 | $37 |
| Injection, regadenoson, 0.1 mg | 24 | $803 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 31 | $763 | $25 |
| Heart muscle strain imaging | 17 | $656 | $39 |
| Heart rhythm recording of continous external ekg over 8-15 days | 40 | $459 | $11 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 21 | $448 | $21 |
| Ultrasound of heart, follow-up | 17 | $330 | $19 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 12 | $259 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $60 | $3 |
Who their Medicare patients are
929 Original Medicare patients in 2024. Average age 77 · Under 65 6% · 85 and older 24% · Women 51% · Also on Medicaid 47% · Health risk score 1.91. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 42% · Coronary heart disease 39% · Chronic kidney disease 39% · Heart failure 36% · Atrial fibrillation 36% · Depression 22% · COPD 21% · Cancer 17% · Dementia 17% · Stroke 14%.
The office billed $900,436, Medicare allowed $261,609 and paid $189,792; for 3,048 services of 50 kinds; $1,194 of it was for drugs given in the office and $188,599 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 929 | 3,048 | 77 | 1.91 | $900,436 | $189,792 |
| 2023 | 828 | 2,785 | 78 | 1.88 | $900,674 | $207,961 |
| 2022 | 890 | 2,908 | 77 | 1.96 | $902,319 | $216,944 |
| 2021 | 816 | 2,487 | 76 | 1.93 | $752,185 | $193,549 |
| 2020 | 877 | 2,442 | 76 | 2.10 | $687,310 | $159,969 |
| 2019 | 1,146 | 3,130 | 76 | 2.05 | $919,266 | $214,559 |
| 2018 | 1,180 | 3,045 | 75 | 2.16 | $777,867 | $170,731 |
| 2017 | 1,372 | 3,219 | 75 | 2.09 | $713,585 | $166,506 |
| 2016 | 1,412 | 3,697 | 75 | 2.12 | $813,709 | $193,004 |
| 2015 | 1,081 | 3,041 | 76 | 1.94 | $919,488 | $200,414 |
| 2014 | 31 | 31 | 74 | 1.51 | $14,190 | $3,739 |
| 2013 | 15 | 18 | 74 | 1.59 | $6,853 | $1,821 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 31 services
| Return visit (30+ min) | 327 | $61,209 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $25,555 | $189 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 35 | $16,465 | $470 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $11,741 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 186 | $10,170 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $10,091 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $9,708 | $72 |
| Short return visit (20+ min) | 97 | $9,073 | $81 |
| New patient visit (45+ min) | 57 | $8,661 | $152 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 29 | $6,741 | $232 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 35 | $5,286 | $76 |
| Injection, regadenoson, 0.1 mg | 32 | $5,265 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 336 | $5,031 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,224 | $119 |
| Programming of dual lead pacemaker system | 19 | $2,305 | $72 |
| 3d radiographic procedure | 77 | $1,985 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 32 | $1,692 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 135 | $1,236 | $7 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 16 | $1,186 | $70 |
| Injection, perflutren lipid microspheres, per ml | 17 | $1,151 | $36 |
| External shock to heart to regulate heart beat | 11 | $1,089 | $99 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 25 | $1,005 | $40 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 32 | $819 | $26 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 24 | $555 | $23 |
| Heart muscle strain imaging | 13 | $547 | $39 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 23 | $490 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 12 | $263 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 22 | $261 | $12 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 21 | $257 | $12 |
| Injection, dobutamine hydrochloride, per 250 mg | 11 | $78 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $39 | $3 |
2022: 29 services
| Return visit (30+ min) | 324 | $62,969 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 144 | $26,648 | $184 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 38 | $18,133 | $477 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $11,831 | $58 |
| Short return visit (20+ min) | 120 | $11,823 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $11,179 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,455 | $169 |
| New patient visit (45+ min) | 59 | $8,773 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $7,904 | $92 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 40 | $7,104 | $89 |
| Injection, regadenoson, 0.1 mg | 33 | $6,386 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 345 | $5,528 | $13 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $5,288 | $240 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,074 | $107 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 225 | $2,414 | $7 |
| Programming of dual lead pacemaker system | 19 | $2,224 | $67 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,554 | $97 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 30 | $1,293 | $43 |
| Ultrasound of heart blood flow, valves and chambers | 24 | $1,279 | $53 |
| Injection, perflutren lipid microspheres, per ml | 12 | $867 | $36 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $862 | $66 |
| 3d radiographic procedure | 30 | $690 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 25 | $642 | $26 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $464 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 18 | $399 | $22 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 16 | $359 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 20 | $263 | $13 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 15 | $206 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $56 | $3 |
2021: 27 services
| Return visit (30+ min) | 304 | $60,156 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 108 | $21,998 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 28 | $13,659 | $488 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $13,069 | $177 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 194 | $11,233 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $8,633 | $64 |
| New patient visit (45+ min) | 55 | $8,086 | $147 |
| Short return visit (20+ min) | 76 | $7,989 | $82 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 27 | $6,449 | $239 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $5,783 | $90 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 31 | $5,573 | $90 |
| Injection, regadenoson, 0.1 mg | 28 | $5,210 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $5,157 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,157 | $113 |
| Programming of dual lead pacemaker system | 20 | $2,161 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 169 | $1,651 | $8 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,285 | $99 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,019 | $68 |
| Injection, perflutren lipid microspheres, per ml | 13 | $956 | $38 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $933 | $72 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 29 | $780 | $27 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $775 | $55 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 22 | $484 | $22 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 12 | $274 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 15 | $244 | $16 |
| Ultrasound of heart, follow-up | 11 | $208 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 21 | $58 | $3 |
2020: 26 services
| Return visit (30+ min) | 275 | $43,635 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $18,277 | $203 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 251 | $15,374 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $13,123 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 84 | $10,486 | $66 |
| New patient visit (45+ min) | 62 | $8,701 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $6,261 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $6,037 | $16 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $5,692 | $126 |
| Short return visit (20+ min) | 51 | $4,368 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 253 | $2,645 | $8 |
| Programming of dual lead pacemaker system | 23 | $2,274 | $61 |
| Telephone medical discussion with physician, 11-20 minutes | 32 | $2,234 | $68 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 13 | $2,209 | $170 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,560 | $71 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,506 | $100 |
| External shock to heart to regulate heart beat | 11 | $1,249 | $96 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $986 | $55 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 22 | $527 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $475 | $26 |
| External ekg recording for more than 48 hours up to 21 days | 18 | $471 | $26 |
| Ultrasound of heart, follow-up | 18 | $439 | $24 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 12 | $280 | $23 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $84 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $56 | $3 |
| Injection, dobutamine hydrochloride, per 250 mg | 11 | $47 | None |
2019: 31 services
| Return visit (30+ min) | 309 | $48,989 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 344 | $22,614 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $19,135 | $181 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 96 | $18,887 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 118 | $15,542 | $65 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $12,599 | $504 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $9,840 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 68 | $8,316 | $121 |
| New patient visit (45+ min) | 54 | $8,146 | $151 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 360 | $6,593 | $15 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 23 | $5,278 | $229 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $4,969 | $89 |
| Short return visit (20+ min) | 70 | $4,894 | $61 |
| Injection, regadenoson, 0.1 mg | 24 | $4,388 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 327 | $3,355 | $8 |
| Programming of dual lead pacemaker system | 24 | $2,409 | $54 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,393 | $100 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 29 | $2,141 | $74 |
| External shock to heart to regulate heart beat | 16 | $1,723 | $101 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,181 | $98 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $1,147 | $55 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 15 | $979 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $611 | $27 |
| External ekg recording for more than 48 hours up to 21 days | 23 | $607 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 23 | $535 | $23 |
| Ultrasound of heart, follow-up | 17 | $423 | $24 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 15 | $348 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 25 | $340 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 36 | $106 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $87 | $7 |
| Injection, dobutamine hydrochloride, per 250 mg | 11 | $62 | None |
2018: 25 services
| Return visit (30+ min) | 317 | $49,505 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 317 | $18,298 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $12,462 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $10,756 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 79 | $9,686 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $9,031 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $8,688 | $90 |
| New patient visit (45+ min) | 64 | $8,141 | $127 |
| Short return visit (20+ min) | 83 | $5,671 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 512 | $4,385 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 259 | $4,190 | $15 |
| Programming of dual lead pacemaker system | 41 | $3,183 | $47 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 48 | $2,629 | $55 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,466 | $95 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 28 | $2,214 | $76 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,893 | $95 |
| External shock to heart to regulate heart beat | 16 | $1,444 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 66 | $802 | $12 |
| External ekg recording for more than 48 hours up to 21 days | 22 | $566 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 22 | $494 | $22 |
| Ultrasound of heart, follow-up | 20 | $492 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 17 | $375 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 73 | $197 | $3 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 18 | $165 | $9 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 14 | $95 | $6 |
2017: 23 services
| Return visit (30+ min) | 286 | $47,879 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 356 | $20,985 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $14,625 | $64 |
| New patient visit (45+ min) | 91 | $12,680 | $139 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 96 | $11,377 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $10,096 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 705 | $6,385 | $7 |
| Short return visit (20+ min) | 78 | $5,974 | $64 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 64 | $4,118 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,011 | $93 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 236 | $3,864 | $15 |
| Programming of dual lead pacemaker system | 39 | $3,026 | $48 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 37 | $2,878 | $78 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,134 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 20 | $1,966 | $98 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 60 | $819 | $13 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $801 | $33 |
| Ultrasound of heart, follow-up | 17 | $441 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $299 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 13 | $297 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 72 | $207 | $3 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 13 | $126 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $86 | $6 |
2016: 24 services
| Return visit (30+ min) | 269 | $48,553 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 173 | $27,233 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 443 | $26,991 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 165 | $21,230 | $116 |
| New patient visit (45+ min) | 78 | $11,150 | $143 |
| Short return visit (20+ min) | 92 | $8,687 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,001 | $180 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 727 | $6,978 | $8 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 100 | $6,463 | $65 |
| Programming of dual lead pacemaker system | 45 | $3,417 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 191 | $3,290 | $16 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 34 | $2,879 | $82 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,967 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,956 | $93 |
| External shock to heart to regulate heart beat | 15 | $1,794 | $112 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 99 | $1,298 | $13 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,275 | $98 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $1,123 | $33 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 25 | $576 | $23 |
| Ultrasound of heart, follow-up | 22 | $560 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 113 | $331 | $3 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $317 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 26 | $257 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 21 | $152 | $7 |
2015: 28 services
| Return visit (30+ min) | 244 | $36,916 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 468 | $27,620 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 205 | $26,864 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 158 | $23,783 | $65 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $16,567 | $518 |
| New patient visit (45+ min) | 85 | $11,983 | $141 |
| Short return visit (20+ min) | 106 | $9,972 | $66 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 32 | $5,588 | $87 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 71 | $4,600 | $65 |
| Programming of dual lead pacemaker system | 48 | $4,344 | $52 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 46 | $3,962 | $84 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 62 | $3,815 | $35 |
| Ultrasound of heart with probe in esophagus, with report | 27 | $2,955 | $109 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 254 | $2,382 | $8 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 29 | $1,851 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 97 | $1,659 | $17 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,516 | $89 |
| Long return visit (40+ min) | 11 | $1,503 | $137 |
| Injection, regadenoson, 0.1 mg | 30 | $1,237 | None |
| External shock to heart to regulate heart beat | 11 | $1,172 | $107 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $1,162 | $77 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 72 | $944 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 34 | $806 | $23 |
| Ultrasound of heart, follow-up | 22 | $537 | $23 |
| Ultrasound of heart blood flow, valves and chambers | 27 | $452 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 111 | $337 | $3 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 31 | $316 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $126 | $7 |
2014: 1 service
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,650 | $122 |
2013: 1 service
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,269 | $115 |
Medicaid work
$40,695 in 2024
Medicaid paid $40,695 for 721 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 187 | $18,441 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 207 | $17,241 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 174 | $2,597 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 153 | $2,416 |
| 2024 | 721 | 4 | 29 | $40,695 |
| 2023 | 624 | 4 | 49 | $44,027 |
| 2022 | 721 | 4 | 37 | $25,842 |
| 2021 | 642 | 4 | 37 | $24,909 |
| 2020 | 742 | 4 | 42 | $24,950 |
| 2019 | 711 | 4 | 73 | $14,540 |
| 2018 | 783 | 4 | 72 | $13,820 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 258 | $24,559 |
| Return visit (30+ min) | 166 | $16,155 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 114 | $2,051 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 86 | $1,261 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 202 | $18,315 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 345 | $3,683 |
| Return visit (30+ min) | 94 | $3,200 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 80 | $644 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 242 | $17,478 |
| Return visit (30+ min) | 70 | $3,673 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 227 | $2,648 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 103 | $1,110 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 282 | $18,710 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 306 | $2,807 |
| Return visit (30+ min) | 90 | $2,735 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 64 | $698 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 231 | $11,492 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 391 | $2,427 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 75 | $384 |
| Return visit (30+ min) | 14 | $236 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 229 | $9,427 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 468 | $2,684 |
| Return visit (30+ min) | 71 | $1,647 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 15 | $63 |
Drugs they prescribed that Part D paid
$1,051,136
Pharmacies billed $1,051,136 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,995) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,088 generic and 907 brand-name prescriptions · $1,051,136 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 492 | $582,428 | $1,184 |
| Entresto | 86 | $112,501 | $1,308 |
| Xarelto | 66 | $78,767 | $1,193 |
| Jardiance | 72 | $66,400 | $922 |
| Multaq | 40 | $54,562 | $1,364 |
See all 45 drugs
| Eliquis | 492 | $582,428 | $1,184 |
| Entresto | 86 | $112,501 | $1,308 |
| Xarelto | 66 | $78,767 | $1,193 |
| Jardiance | 72 | $66,400 | $922 |
| Multaq | 40 | $54,562 | $1,364 |
| Praluent | 47 | $30,176 | $642 |
| Repatha Sureclick | 29 | $21,385 | $737 |
| Vascepa | 14 | $6,985 | $499 |
| Metoprolol | 379 | $6,770 | $18 |
| Sildenafil Citrate | 14 | $4,749 | $339 |
| Atorvastatin | 382 | $4,023 | $11 |
| Bumetanide | 58 | $3,761 | $65 |
| Losartan | 202 | $2,617 | $13 |
| Carvedilol | 208 | $2,431 | $12 |
| Rosuvastatin | 123 | $2,233 | $18 |
| Valsartan | 54 | $2,118 | $39 |
| Diltiazem 24hr Er (Cd) | 62 | $1,985 | $32 |
| Potassium Chloride | 66 | $1,407 | $21 |
| Amlodipine Besylate | 221 | $1,346 | $6 |
| Furosemide | 262 | $1,204 | $5 |
| Amiodarone | 27 | $1,007 | $37 |
| Ezetimibe | 79 | $933 | $12 |
| Lisinopril | 174 | $910 | $5 |
| Felodipine Er | 15 | $888 | $59 |
| Omega-3 Acid Ethyl Esters | 12 | $853 | $71 |
| Spironolactone | 86 | $705 | $8 |
| Metoprolol | 83 | $586 | $7 |
| Pravastatin | 40 | $544 | $14 |
| Chlorthalidone | 33 | $470 | $14 |
| Isosorbide Mononitrate Er | 24 | $418 | $17 |
| Clonidine | 27 | $356 | $13 |
| Digoxin | 12 | $327 | $27 |
| Nifedipine Er | 16 | $322 | $20 |
| Labetalol | 14 | $283 | $20 |
| Ramipril | 26 | $283 | $11 |
| Losartan-Hydrochlorothiazide | 17 | $259 | $15 |
| Benazepril | 20 | $242 | $12 |
| Irbesartan | 13 | $230 | $18 |
| Clopidogrel | 51 | $213 | $4 |
| Hydrochlorothiazide | 91 | $211 | $2 |
| Triamterene-Hydrochlorothiazid | 14 | $165 | $12 |
| Simvastatin | 12 | $136 | $11 |
| Hydralazine | 19 | $116 | $6 |
| Nitroglycerin | 13 | $111 | $9 |
| Atenolol | 25 | $83 | $3 |
Year by year
| 2024 | 3,995 | 516 | 0% (0) | 23% | $1,051,136 |
| 2023 | 3,799 | 481 | 0% (0) | 21% | $1,079,143 |
| 2022 | 3,605 | 437 | None | None | $891,291 |
| 2021 | 3,233 | 406 | 0% (0) | None | $775,891 |
| 2020 | 3,048 | 383 | None | None | $683,252 |
| 2019 | 2,966 | 393 | 0% (0) | None | $585,389 |
| 2018 | 3,264 | 382 | 0% (0) | None | $584,371 |
| 2017 | 2,941 | 330 | 0% (0) | None | $468,115 |
| 2016 | 2,588 | 296 | None | None | $366,863 |
| 2015 | 1,485 | 219 | None | 23% | $129,865 |
| 2014 | 148 | 32 | 0% (0) | 29% | $7,599 |
| 2013 | 113 | 50 | None | 29% | $5,351 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Eliquis | 459 | $571,195 | $1,244 |
| Bosentan | 13 | $100,554 | $7,735 |
| Xarelto | 85 | $85,888 | $1,010 |
| Entresto | 59 | $80,077 | $1,357 |
| Multaq | 30 | $47,917 | $1,597 |
| Praluent | 68 | $45,676 | $672 |
| Jardiance | 35 | $34,394 | $983 |
| Metoprolol | 414 | $10,078 | $24 |
| Atorvastatin | 412 | $6,531 | $16 |
| Valsartan | 63 | $6,418 | $102 |
| Bumetanide | 50 | $3,895 | $78 |
| Losartan | 164 | $3,597 | $22 |
| Carvedilol | 186 | $3,311 | $18 |
| Rosuvastatin | 96 | $3,160 | $33 |
| Amlodipine Besylate | 204 | $2,854 | $14 |
| Diltiazem 24hr Er (Cd) | 45 | $2,786 | $62 |
| Lisinopril | 165 | $2,055 | $12 |
| Furosemide | 283 | $1,957 | $7 |
| Potassium Chloride | 44 | $1,943 | $44 |
| Ezetimibe | 48 | $1,883 | $39 |
| Amiodarone | 40 | $1,619 | $40 |
| Metoprolol | 87 | $1,503 | $17 |
| Isosorbide Mononitrate Er | 40 | $1,236 | $31 |
| Spironolactone | 90 | $1,166 | $13 |
| Clopidogrel | 56 | $1,088 | $19 |
| Digoxin | 21 | $781 | $37 |
| Ramipril | 30 | $561 | $19 |
| Labetalol | 11 | $533 | $48 |
| Pravastatin | 37 | $489 | $13 |
| Losartan-Hydrochlorothiazide | 19 | $443 | $23 |
| Hydralazine | 18 | $407 | $23 |
| Irbesartan | 12 | $361 | $30 |
| Clonidine | 26 | $342 | $13 |
| Chlorthalidone | 19 | $339 | $18 |
| Hydrochlorothiazide | 91 | $336 | $4 |
| Nitroglycerin | 12 | $210 | $17 |
| Atenolol | 23 | $163 | $7 |
2022: 41 drugs
| Eliquis | 537 | $542,701 | $1,011 |
| Xarelto | 77 | $85,246 | $1,107 |
| Entresto | 53 | $55,573 | $1,049 |
| Multaq | 31 | $38,834 | $1,253 |
| Praluent | 57 | $37,039 | $650 |
| Bosentan | 11 | $16,833 | $1,530 |
| Repatha Sureclick | 14 | $10,833 | $774 |
| Vascepa | 14 | $8,251 | $589 |
| Metoprolol | 390 | $7,627 | $20 |
| Atorvastatin | 391 | $5,040 | $13 |
| Amiodarone | 66 | $3,651 | $55 |
| Ezetimibe | 50 | $2,743 | $55 |
| Valsartan | 31 | $2,519 | $81 |
| Rosuvastatin | 67 | $2,279 | $34 |
| Carvedilol | 154 | $2,262 | $15 |
| Furosemide | 270 | $2,208 | $8 |
| Bumetanide | 26 | $2,120 | $82 |
| Diltiazem 24hr Er (Cd) | 40 | $2,016 | $50 |
| Losartan | 133 | $1,869 | $14 |
| Amlodipine Besylate | 211 | $1,781 | $8 |
| Nifedipine Er | 17 | $1,616 | $95 |
| Lisinopril | 141 | $1,387 | $10 |
| Carvedilol Er | 12 | $1,351 | $113 |
| Potassium Chloride | 37 | $1,262 | $34 |
| Clopidogrel | 71 | $1,155 | $16 |
| Metoprolol | 91 | $1,022 | $11 |
| Isosorbide Dinitrate | 12 | $887 | $74 |
| Pravastatin | 46 | $746 | $16 |
| Digoxin | 18 | $718 | $40 |
| Spironolactone | 45 | $569 | $13 |
| Hydralazine | 21 | $531 | $25 |
| Chlorthalidone | 24 | $514 | $21 |
| Ramipril | 27 | $467 | $17 |
| Isosorbide Mononitrate Er | 24 | $466 | $19 |
| Nitroglycerin | 24 | $361 | $15 |
| Clonidine | 15 | $300 | $20 |
| Hydrochlorothiazide | 77 | $271 | $4 |
| Torsemide | 13 | $242 | $19 |
| Atenolol | 21 | $214 | $10 |
| Benazepril | 15 | $173 | $12 |
| Warfarin | 15 | $104 | $7 |
2021: 40 drugs
| Eliquis | 519 | $457,061 | $881 |
| Xarelto | 77 | $68,718 | $892 |
| Bosentan | 13 | $45,945 | $3,534 |
| Entresto | 34 | $36,935 | $1,086 |
| Multaq | 31 | $27,901 | $900 |
| Praluent | 36 | $17,625 | $490 |
| Veltassa | 11 | $11,919 | $1,084 |
| Vascepa | 14 | $11,023 | $787 |
| Metoprolol | 364 | $9,224 | $25 |
| Bystolic | 11 | $7,227 | $657 |
| Atorvastatin | 311 | $5,327 | $17 |
| Ezetimibe | 48 | $4,083 | $85 |
| Diltiazem 24hr Er (Cd) | 51 | $3,110 | $61 |
| Carvedilol | 177 | $2,664 | $15 |
| Valsartan | 44 | $2,338 | $53 |
| Rosuvastatin | 48 | $2,296 | $48 |
| Bumetanide | 26 | $2,216 | $85 |
| Losartan | 116 | $1,967 | $17 |
| Furosemide | 241 | $1,822 | $8 |
| Amiodarone | 41 | $1,648 | $40 |
| Amlodipine Besylate | 197 | $1,537 | $8 |
| Potassium Chloride | 54 | $1,348 | $25 |
| Lisinopril | 101 | $815 | $8 |
| Metoprolol | 71 | $758 | $11 |
| Pravastatin | 46 | $657 | $14 |
| Clopidogrel | 32 | $626 | $20 |
| Nifedipine Er | 12 | $626 | $52 |
| Digoxin | 17 | $601 | $35 |
| Spironolactone | 52 | $567 | $11 |
| Isosorbide Mononitrate Er | 26 | $549 | $21 |
| Ramipril | 20 | $462 | $23 |
| Chlorthalidone | 17 | $387 | $23 |
| Hydralazine | 19 | $259 | $14 |
| Clonidine | 18 | $254 | $14 |
| Nitroglycerin | 17 | $233 | $14 |
| Warfarin | 15 | $226 | $15 |
| Hydrochlorothiazide | 67 | $197 | $3 |
| Simvastatin | 16 | $182 | $11 |
| Atenolol | 17 | $178 | $10 |
| Benazepril | 11 | $127 | $12 |
2020: 41 drugs
| Eliquis | 455 | $386,143 | $849 |
| Bosentan | 12 | $67,996 | $5,666 |
| Xarelto | 49 | $49,591 | $1,012 |
| Multaq | 30 | $28,006 | $934 |
| Praluent | 27 | $23,482 | $870 |
| Entresto | 17 | $17,768 | $1,045 |
| Brilinta | 21 | $15,407 | $734 |
| Metoprolol | 291 | $8,271 | $28 |
| Atorvastatin | 350 | $6,629 | $19 |
| Sildenafil Citrate | 19 | $4,742 | $250 |
| Amiodarone | 73 | $3,380 | $46 |
| Diltiazem 24hr Er (Cd) | 36 | $3,011 | $84 |
| Carvedilol | 188 | $2,207 | $12 |
| Rosuvastatin | 48 | $1,951 | $41 |
| Ezetimibe | 31 | $1,946 | $63 |
| Furosemide | 189 | $1,602 | $8 |
| Eplerenone | 13 | $1,525 | $117 |
| Potassium Chloride | 56 | $1,453 | $26 |
| Losartan | 102 | $1,324 | $13 |
| Amlodipine Besylate | 199 | $1,291 | $6 |
| Bumetanide | 16 | $1,278 | $80 |
| Pravastatin | 43 | $999 | $23 |
| Lisinopril | 103 | $901 | $9 |
| Nifedipine Er | 11 | $822 | $75 |
| Clopidogrel | 50 | $758 | $15 |
| Irbesartan | 11 | $649 | $59 |
| Isosorbide Mononitrate Er | 28 | $643 | $23 |
| Digoxin | 17 | $548 | $32 |
| Chlorthalidone | 13 | $547 | $42 |
| Hydralazine | 25 | $486 | $19 |
| Valsartan | 15 | $484 | $32 |
| Ramipril | 26 | $480 | $18 |
| Metoprolol | 60 | $424 | $7 |
| Pantoprazole | 15 | $385 | $26 |
| Spironolactone | 33 | $361 | $11 |
| Warfarin | 25 | $285 | $11 |
| Hydrochlorothiazide | 65 | $217 | $3 |
| Nitroglycerin | 16 | $214 | $13 |
| Atenolol | 26 | $197 | $8 |
| Clonidine | 17 | $177 | $10 |
| Simvastatin | 14 | $71 | $5 |
2019: 36 drugs
| Eliquis | 386 | $307,002 | $795 |
| Xarelto | 62 | $48,255 | $778 |
| Multaq | 37 | $26,819 | $725 |
| Praluent | 24 | $23,898 | $996 |
| Brilinta | 32 | $15,003 | $469 |
| Atorvastatin | 349 | $8,203 | $24 |
| Metoprolol | 247 | $7,495 | $30 |
| Amiodarone | 65 | $4,295 | $66 |
| Carvedilol | 234 | $2,856 | $12 |
| Potassium Chloride | 47 | $1,801 | $38 |
| Amlodipine Besylate | 215 | $1,559 | $7 |
| Rosuvastatin | 29 | $1,528 | $53 |
| Lisinopril | 171 | $1,414 | $8 |
| Furosemide | 166 | $1,274 | $8 |
| Ezetimibe | 15 | $1,203 | $80 |
| Diltiazem 24hr Er (Cd) | 27 | $1,197 | $44 |
| Omega-3 Acid Ethyl Esters | 20 | $1,187 | $59 |
| Losartan | 79 | $1,067 | $14 |
| Bumetanide | 17 | $970 | $57 |
| Cartia Xt | 25 | $908 | $36 |
| Nifedipine Er | 13 | $772 | $59 |
| Metoprolol | 87 | $722 | $8 |
| Pravastatin | 26 | $717 | $28 |
| Clopidogrel | 45 | $637 | $14 |
| Hydralazine | 22 | $633 | $29 |
| Isosorbide Mononitrate Er | 18 | $588 | $33 |
| Ramipril | 24 | $486 | $20 |
| Warfarin | 24 | $382 | $16 |
| Spironolactone | 45 | $352 | $8 |
| Pindolol | 11 | $276 | $25 |
| Digoxin | 11 | $275 | $25 |
| Clonidine | 24 | $221 | $9 |
| Triamterene-Hydrochlorothiazid | 11 | $201 | $18 |
| Nitroglycerin | 13 | $188 | $14 |
| Atenolol | 18 | $172 | $10 |
| Hydrochlorothiazide | 41 | $127 | $3 |
2018: 45 drugs
| Eliquis | 378 | $252,760 | $669 |
| Letairis | 11 | $109,967 | $9,997 |
| Xarelto | 93 | $49,315 | $530 |
| Praluent | 25 | $29,485 | $1,179 |
| Multaq | 42 | $28,640 | $682 |
| Pradaxa | 26 | $21,794 | $838 |
| Metoprolol | 256 | $8,273 | $32 |
| Atorvastatin | 335 | $7,614 | $23 |
| Brilinta | 16 | $7,199 | $450 |
| Carvedilol | 245 | $2,748 | $11 |
| Amiodarone | 65 | $2,487 | $38 |
| Omega-3 Acid Ethyl Esters | 17 | $2,090 | $123 |
| Valsartan | 22 | $1,928 | $88 |
| Cartia Xt | 66 | $1,846 | $28 |
| Ezetimibe | 12 | $1,655 | $138 |
| Rosuvastatin | 26 | $1,364 | $52 |
| Lisinopril | 161 | $1,358 | $8 |
| Potassium Chloride | 60 | $1,339 | $22 |
| Amlodipine Besylate | 196 | $1,308 | $7 |
| Olmesartan Medoxomil | 13 | $1,262 | $97 |
| Furosemide | 218 | $1,058 | $5 |
| Losartan | 86 | $1,032 | $12 |
| Digox | 18 | $978 | $54 |
| Irbesartan | 19 | $878 | $46 |
| Metoprolol | 127 | $842 | $7 |
| Dilt-Xr | 14 | $704 | $50 |
| Nifedipine Er | 17 | $699 | $41 |
| Ramipril | 37 | $680 | $18 |
| Pravastatin | 23 | $679 | $30 |
| Isosorbide Mononitrate Er | 36 | $642 | $18 |
| Hydralazine | 27 | $580 | $21 |
| Clopidogrel | 61 | $580 | $10 |
| Bumetanide | 14 | $563 | $40 |
| Warfarin | 26 | $448 | $17 |
| Torsemide | 16 | $269 | $17 |
| Pantoprazole | 18 | $267 | $15 |
| Sotalol | 14 | $261 | $19 |
| Spironolactone | 39 | $247 | $6 |
| Simvastatin | 12 | $246 | $20 |
| Hydrochlorothiazide | 54 | $191 | $4 |
| Triamterene-Hydrochlorothiazid | 12 | $168 | $14 |
| Omeprazole | 12 | $141 | $12 |
| Atenolol | 18 | $121 | $7 |
| Clonidine | 16 | $91 | $6 |
| Losartan-Hydrochlorothiazide | 12 | $81 | $7 |
2017: 42 drugs
| Eliquis | 355 | $197,411 | $556 |
| Letairis | 11 | $106,096 | $9,645 |
| Pradaxa | 33 | $20,368 | $617 |
| Praluent | 16 | $18,616 | $1,163 |
| Xarelto | 31 | $17,280 | $557 |
| Multaq | 23 | $13,656 | $594 |
| Metoprolol | 284 | $7,178 | $25 |
| Atorvastatin | 297 | $6,367 | $21 |
| Valsartan | 34 | $3,629 | $107 |
| Amiodarone | 78 | $2,777 | $36 |
| Omega-3 Acid Ethyl Esters | 15 | $2,686 | $179 |
| Tekturna | 12 | $2,501 | $208 |
| Rosuvastatin | 22 | $1,886 | $86 |
| Olmesartan Medoxomil | 12 | $1,593 | $133 |
| Flecainide Acetate | 18 | $1,236 | $69 |
| Carvedilol | 203 | $1,167 | $6 |
| Metoprolol | 129 | $1,029 | $8 |
| Amlodipine Besylate | 192 | $1,010 | $5 |
| Potassium Chloride | 47 | $972 | $21 |
| Lisinopril | 143 | $950 | $7 |
| Ramipril | 35 | $734 | $21 |
| Warfarin | 44 | $711 | $16 |
| Cartia Xt | 35 | $705 | $20 |
| Furosemide | 149 | $694 | $5 |
| Isosorbide Mononitrate Er | 45 | $677 | $15 |
| Irbesartan | 21 | $652 | $31 |
| Digoxin | 12 | $624 | $52 |
| Hydralazine | 23 | $623 | $27 |
| Nifedipine Er | 13 | $619 | $48 |
| Diltiazem 24hr Er | 22 | $605 | $28 |
| Clopidogrel | 64 | $459 | $7 |
| Losartan | 59 | $445 | $8 |
| Pravastatin | 22 | $428 | $19 |
| Spironolactone | 52 | $421 | $8 |
| Pantoprazole | 11 | $187 | $17 |
| Torsemide | 17 | $177 | $10 |
| Simvastatin | 13 | $134 | $10 |
| Benazepril | 16 | $116 | $7 |
| Hydrochlorothiazide | 23 | $81 | $4 |
| Atenolol | 15 | $75 | $5 |
| Omeprazole | 11 | $74 | $7 |
| Clonidine | 14 | $36 | $3 |
2016: 39 drugs
| Eliquis | 292 | $148,666 | $509 |
| Xarelto | 29 | $17,526 | $604 |
| Pradaxa | 25 | $15,255 | $610 |
| Multaq | 23 | $12,959 | $563 |
| Benicar | 16 | $5,195 | $325 |
| Metoprolol | 213 | $5,190 | $24 |
| Atorvastatin | 290 | $4,996 | $17 |
| Valsartan | 35 | $4,499 | $129 |
| Tekturna | 15 | $3,584 | $239 |
| Amiodarone | 85 | $3,467 | $41 |
| Sildenafil | 12 | $1,643 | $137 |
| Carvedilol | 198 | $1,530 | $8 |
| Amlodipine Besylate-Benazepril | 17 | $1,360 | $80 |
| Potassium Chloride | 46 | $1,347 | $29 |
| Ramipril | 27 | $972 | $36 |
| Lisinopril | 130 | $928 | $7 |
| Chlorthalidone | 17 | $847 | $50 |
| Rosuvastatin | 14 | $808 | $58 |
| Amlodipine Besylate | 127 | $740 | $6 |
| Metoprolol | 104 | $711 | $7 |
| Furosemide | 154 | $710 | $5 |
| Irbesartan | 18 | $688 | $38 |
| Cartia Xt | 20 | $568 | $28 |
| Isosorbide Mononitrate Er | 43 | $561 | $13 |
| Clopidogrel | 43 | $549 | $13 |
| Pravastatin | 14 | $528 | $38 |
| Losartan | 57 | $507 | $9 |
| Spironolactone | 49 | $492 | $10 |
| Warfarin | 43 | $471 | $11 |
| Hydralazine | 21 | $436 | $21 |
| Nifedipine Er | 12 | $377 | $31 |
| Levothyroxine | 13 | $291 | $22 |
| Benazepril | 12 | $153 | $13 |
| Pantoprazole | 14 | $138 | $10 |
| Hydrochlorothiazide | 32 | $135 | $4 |
| Clonidine | 18 | $96 | $5 |
| Atenolol | 13 | $68 | $5 |
| Simvastatin | 14 | $68 | $5 |
| Mexiletine | 12 | $44 | $4 |
2015: 29 drugs
| Eliquis | 128 | $52,014 | $406 |
| Xarelto | 28 | $12,718 | $454 |
| Multaq | 17 | $8,222 | $484 |
| Benicar | 16 | $3,219 | $201 |
| Valsartan | 29 | $3,137 | $108 |
| Metoprolol | 79 | $2,570 | $33 |
| Atorvastatin | 135 | $2,515 | $19 |
| Amiodarone | 46 | $2,096 | $46 |
| Potassium Chloride | 36 | $810 | $23 |
| Carvedilol | 101 | $722 | $7 |
| Nifedipine Er | 13 | $676 | $52 |
| Ramipril | 17 | $542 | $32 |
| Amlodipine Besylate | 104 | $542 | $5 |
| Lisinopril | 92 | $467 | $5 |
| Chlorthalidone | 12 | $438 | $37 |
| Metoprolol | 75 | $406 | $5 |
| Furosemide | 100 | $372 | $4 |
| Clopidogrel | 21 | $348 | $17 |
| Cartia Xt | 15 | $315 | $21 |
| Losartan | 40 | $211 | $5 |
| Warfarin | 23 | $204 | $9 |
| Torsemide | 15 | $199 | $13 |
| Isosorbide Mononitrate Er | 24 | $191 | $8 |
| Spironolactone | 27 | $186 | $7 |
| Pantoprazole | 15 | $164 | $11 |
| Clonidine | 16 | $155 | $10 |
| Hydrochlorothiazide | 24 | $108 | $5 |
| Benazepril | 11 | $49 | $4 |
| Atenolol | 11 | $33 | $3 |
2014: 3 drugs
| Carvedilol | 27 | $257 | $10 |
| Lisinopril | 11 | $67 | $6 |
| Furosemide | 13 | $58 | $4 |
2013: 2 drugs
| Carvedilol | 13 | $136 | $10 |
| Metoprolol | 11 | $53 | $5 |
Money from drug and device companies
$21 in 2022
| 2022 | 1 | 1 | None | $21 |
| 2021 | 2 | 3 | None | $61 |
| 2020 | 8 | 22 | None | $736 |
| 2019 | 10 | 28 | None | $643 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bardy Diagnostics | Carnation Ambulatory Monitor | $21 | 1 payment
|
See the published payment
| Bardy Diagnostics | Meals · 2022-10-13 | Carnation Ambulatory Monitor | $21 |
See earlier years (2021, 2020, 2019)
2021: $61
| E.R. Squibb & Sons L.L.C. | Eliquis | $46 | 2 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $15 | 1 payment
|
2020: $736
| Esperion Therapeutics | Nexletol | $518 | 11 payments
|
| Janssen Pharmaceuticals | Xarelto | $74 | 3 payments
|
| CathWorks | Ffrangio System | $47 | 2 payments
|
| Amgen | Repatha | $41 | 2 payments
|
| iRhythm Technologies | Zio Patch | $16 | 1 payment
|
| Pfizer | Eliquis | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $13 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $12 | 1 payment
|
2019: $643
| Amgen | Repatha | $158 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $125 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $95 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $85 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $55 | 3 payments
|
| iRhythm Technologies | Zio Patch | $33 | 2 payments
|
| HeartFlow | None | $24 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $23 | 1 payment
|
| Astellas Pharma US | Lexiscan | $22 | 1 payment
|
| Pfizer | Chantix | $21 | 1 payment
|
Professional record
- NPI
- 1114152717
- Licence
- CA A107787California A107787: Current · expires 2026-11-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 2100 Webster St, Suite 516, San Francisco, CA, 94115
- NPI first listed
- 2009-05-27
- NPI last updated
- 2016-07-19
This is when the NPI record was last certified, not a medical board exam.